New shot for lupus passes first safety check in small study

NCT ID NCT06955598

Completed Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested an experimental drug called SHR-2173 in 30 adults with systemic lupus erythematosus (SLE). The drug was given as multiple injections under the skin. The main goal was to see if it is safe and tolerable, and to measure how the body processes it. This is a first step toward possibly finding a new way to manage lupus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-2173 (an experimental drug given as injections under the skin)
What this could lead to: If safe and effective, SHR-2173 could become a new treatment option to help control lupus symptoms and reduce disease activity.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. The drug may not work in larger studies or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Renji Hospital affiliated to Shanghai Jiaotong

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.